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mRNA and protein expression and decreased ERα, with an 
increased ratio of AR/ER, suggesting preferential androgenic 
vs estrogenic pathway activation.
Conclusions Our results demonstrate for the first time 
that TAD decreases ARO expression and increases AR 
protein expression in human SAOS-2, strongly suggest-
ing a new control of steroid hormones pathway by PDE5i. 
These findings might represent the first evidence of trans-
lational actions of PDE5i on AR, which leads to hypoth-
esize a growing relevance of this molecule in men with 
prostate cancer long-term treated with TAD for sexual 
rehabilitation.
Keywords Tadalafil · Osteoblasts · Aromatase · Androgen 
receptor · Estrogen receptor
Introduction
It is well known that phosphodiesterases (PDEs) catalyze 
the hydrolysis of cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP), to the 5′ 
nucleotide monophosphate [1]. Eleven different PDE fami-
lies (PDE1-11) have been described throughout the body, 
each family containing subfamilies and multiple splice 
variance, differing in selectivity for cyclic nucleotides, 
sensitivity to inhibitors and activators, physiological roles, 
and tissue distribution. In the last decade, several pharma-
ceutical compounds, which selectively inhibit the catalytic 
activities of PDE, have been developed for the treatment of 
various diseases, but only PDE5 inhibitors (PDE5i) reached 
clinical application mainly for treating male erectile dys-
function (ED) [2].
Interestingly, several studies demonstrated that small 
PDE5 amounts are present in different extra-genital tissues 
Abstract 
Purpose Phosphodiesterase type-5 inhibitor (PDE5i) 
tadalafil administration in men with erectile dysfunction is 
associated with increased testosterone/estradiol ratio, lead-
ing to hypothesize a potential increased effect of androgen 
action on target tissues. We aimed to characterize, in a cel-
lular model system in vitro, the potential modulation of 
aromatase and sex steroid hormone receptors upon expo-
sure to tadalafil (TAD).
Methods Human osteoblast-like cells SAOS-2 were cho-
sen as an in vitro model system since osteoblasts are target 
of steroid hormones. Cells were tested for viability upon 
TAD exposure, which increased cell proliferation. Then, 
cells were treated with/without TAD for several times to 
evaluate potential modulation in PDE5, aromatase (ARO), 
androgen (AR) and estrogen (ER) receptor expression.
Results Osteoblasts express significant levels of both PDE5 
mRNA and protein. Exposure of cells to increasing concen-
trations of TAD (10−8–10−7 M) decreased PDE5 mRNA and 
protein expression. Also, TAD inhibited ARO mRNA and 
protein expression leading to an increase in testosterone lev-
els in the supernatants. Interestingly, TAD increased total AR 
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(i.e., skeletal muscle, heart, lung, adrenal gland) [3] and 
Ahlström and Lamberg-Allardt firstly demonstrated that 
PDE5 is present in UMR-106 osteoblast-like cells [4]. Suc-
cessive studies have suggested that PDE5i might have some 
detrimental effects on osteoblastic activity both in vitro and 
in animal models [5]. Despite this, the chronic use of any 
PDE5 inhibitor has never been associated with reduced 
bone mineral density in humans.
Men suffering from erectile dysfunction (ED) have 
androgen levels significantly lower than normal one and 
it is demonstrated that the effects of two different PDE5 
inhibitors treatments, Sildenafil and Tadalafil (TAD), are 
able to revert testosterone reduction, and thereby reduc-
ing LH levels, probably due to the higher frequency of full 
sexual intercourse [6]. The rationale of the present study 
started from a clinical observation suggesting that the con-
tinuous administration of the PDE5i tadalafil in men with 
ED is associated with an increase of serum testosterone/
estradiol ratio [7]. In addition, our previous studies had 
shown that PDE5 is also expressed in human adipocytes 
in vitro and that TAD exposure modulates ARO expres-
sion and activity [8]. The actions of PDE5 inhibitors upon 
testosterone production have been studied extensively in 
rat models. Interestingly, it has been recently shown that 
inhibition of PDE5 activity upon prolonged sildenafil treat-
ment, increased serum testosterone level and Leydig cells’ 
steroidogenic capacity by stimulating cAMP and cGMP 
signaling pathway [9]. Also, acute administration of silde-
nafil stimulates testosterone production, suggesting impli-
cations for sexual activity regulation [10]. Due to these 
results, it might be postulated a modulation by TAD of 
steroid receptors through which hormone action is exerted. 
Thus, the present study was designed to evaluate the mech-
anism of action of PDE5i in human androgen/estrogen 
target tissues to further characterize in vitro the effects of 
exposure to the selective PDE5i TAD on both ARO expres-
sion and sex steroid receptors in osteoblastic cells, well-
known steroid target tissue.
Materials and methods
Cell culture and treatment
Human SAOS-2 osteoblastic cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 2 mM l-glutamine, 100 U/mL penicillin/streptomy-
cin, 10 % fetal bovine serum (FBS), at 37 °C and 5 % CO2 
in a humidified incubator. All buffers, media and reagents 
were purchased from Euroclone. Osteoblastic cells were 
switched to phenol red-free DMEM and treated with dif-
ferent doses of TAD (10−8–10−7 M) for 24, 48 h. Tada-
lafil (kindly supplied by ELI Lilly ICOS Corporation, 
Indianapolis, IN, USA) was dissolved in dimethylsulfoxide 
and added to cells at the concentrations indicated for each 
experiment. At the end of incubations, media were removed 
and centrifuged at 250 g for 12 min, and supernatants were 
saved for the ELISA assays.
MTT assay
The effect of TAD on proliferation and cell vitality was 
quantified by 3-(4,5-dimethylthiazol-2-y1)-2,5-diphe-
nyltetrazolium bromide reduction assay (MTT assay, 
Sigma). Thus, 1.5 × 104 cells/well were seeded in 96-well 
culture plate and treated in quadruplicate with different 
doses of TAD (10−8–10−7 M). After 1, 2, 3, 4 and 5 days 
of TAD treatment the assay was performed accordingly 
to the manufacturer’s guidelines. Values from each treat-
ment were calculated as percent of the viability versus the 
untreated control.
RNA isolation and quantitative real‑time PCR
For RNA extraction, cells were washed twice with 1X 
phosphate buffer saline (PBS, Euroclone) and total RNA 
was immediately lysated with Trizol (Life Technologies) 
according the manufacturer’s instructions. The purity and 
integrity of total RNA was monitored by electrophoretic 
analysis on denaturating agarose gel; ultraviolet spec-
trophotometry (Biorad) was used for RNA yield evalua-
tion. Total RNA was treated as previously described [11]. 
Quantitative real-time PCR was performed in Abi Prism 
7500 light cycler (Applied Biosystem) using Power SYBR 
Green PCR Master Mix (Applied Biosystem) as indicated 
by manufacturers. All primers were optimized as previ-
ously described [11]. Quantitative RT-PCR sample value 
was normalized for the expression of cyclophilin mRNA. 
The relative level for each gene was calculated using the 
2−ΔΔCt method [12] and reported as arbitrary units (a. u.). 
Each sample was analyzed in duplicate in all experiments.
Protein extraction and Western blot analysis
Following experimental treatments, cells were washed 
with PBS and lysed in fresh ice-cold RIPA buffer (150 mM 
NaCl, 50 mM Tris–HCl, pH 7.5, 500 µM EDTA, 100 µM 
EGTA, 1.0 % Triton X-100, and 1 % sodium deoxycho-
late) supplemented with protease and phosphatase inhibitor 
cocktails (Sigma).
Lysates were precleared by centrifugation and the pro-
tein amount was measured using Micro BCA Protein assay 
Reagent (Thermo Scientific). An equal amount of protein 
extracts (20 μg) was separated in SDS–polyacrylamide 
gels (10–14 %) and transferred to a nitrocellulose mem-
brane (Amersham Biosciences).
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Transfer was verified by Ponceau S staining. The mem-
brane was blocked 60′ at room temperature with 5 % non-
fat dry milk (Cell Signalling Technology) in T-TBS (tris 
buffered saline plus tween 20, 0.01 %). Membranes were 
incubated with primary antibodies diluted as indicated 
by manufacturers, overnight at 4 °C. It was washed three 
times with T-TBS and incubated for 60′ at room tempera-
ture with HRP-labeled secondary antibody in 5 % non-fat 
dry milk. Membranes were then washed three times and 
the signals were visualized using ECL Prime Western blot-
ting detection reagent (GE Healthcare) in the ImageQuant 
LAS4000 instrument (Amersham Biosciences). Quantita-
tive analysis was performed using Imagequant TL Image 
analysis software (GE Healthcare) using beta-actin for 
normalization. The primary antibodies used were: anti-
aromatase (Cell Signalling Technology) anti-androgen 
receptor (Santa Cruz Biotechnology), anti-estrogen recep-
tor α (Santa Cruz Biotechnology), anti-phosphodiesterase 
type-5 (Cell Signalling Technology) anti-β-actin (Cell Sig-
nalling Technology).
ELISA assay
The culture medium of TAD-treated cells exposed to bovine 
serum was recovered for ELISA assays using Estradiol 
ELISA, Testosterone ELISA (Cusabio Biotech Co., LTD.). 
Each experiment was repeated three times. Hormones lev-
els found in the supernatant were corrected per milligram 
of cellular protein of each dish. Data are expressed as pg/
mg protein.
Statistical analysis
All results were expressed as means ± standard errors (SE) 
of at least three independent experiments. p values were 
calculated using the unpaired t test and statistically signifi-
cant differences and were considered significant with val-
ues <0.05.
Results
Osteoblastic cells as tadalafil target
A first set of experiments was performed to evaluate a 
potential cytotoxic effect of TAD on SAOS-2 osteoblastic 
cells by checking cells viability by MTT assay. To address 
this point, cells were treated with different doses of TAD 
up to 5 days. TAD did not exert any toxic effect on SAOS-2 
cells up to 5 days of exposure. By contrast, treated cells 
displayed higher viability in the MTT assay compared to 
the untreated cells (p < 0.05, Fig. 1), indicating that TAD 
stimulates osteoblastic cell proliferation.
To verify whether bone tissue could represent a specific tar-
get tissue of PDE5i, we firstly evaluated the PDE5 expression 
in human SAOS-2. PDE5 mRNA and protein were detected 
in osteoblasts by RT-PCR and Western Blot (Fig. 2a, b), in 
*** 
*** 
* 
* 
100
120
140
160
180
200
1d 2d 3d 4d 5d
V
ia
bl
e 
ce
lls
 (%
)
TAD exposure time (days)
CTL
TAD -8M
TAD -7M
* 
* 
Fig. 1  Cytotoxic assay: Saos-2 cells were treated with different 
TAD concentrations (10−7, 10−8 M) for several interval times (day 1 
through 5). *p < 0.05, ***p < 0.001 versus CTL
A
B
β - Actin
PDE5
CTL                10-8 M               10-7 M       
0
0.5
1
1.5
2
2.5
CTL TAD 10-8M TAD 10-7M
R
el
at
iv
e 
PD
E
5 
pr
ot
ei
n 
am
ou
nt
0.0
0.5
1.0
1.5
2.0
2.5
CTL TAD 10-8M TAD 10-7M
R
el
at
iv
e 
PD
E
5 
m
R
N
A
 le
ve
l
* 
* 
******
C
Fig. 2  Expression of mRNA (a) and protein (b, c) PDE5 in osteo-
blasts. Cells were grown in presence of different TAD concen-
trations (10−7, 10−8 M) for 24 and 48 h, respectively. *p < 0.05, 
***p < 0.0001 versus CTL
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accordance with previous published results in other osteoblas-
tic cells lines [5]. Moreover, 24 h treatment with increasing 
concentration of TAD induced a decrease of PDE5 mRNA 
(p < 0.05, Fig. 2a), also confirmed, after 48 h of treatment, by 
a decreased protein level (p < 0.001, Fig. 2b).
Dose‑dependent effect of TAD on ARO mRNA 
and protein expression
Since our previous data indicated a modulation of ARO by 
TAD in human adipocytes [7], experiments were performed 
to evaluate potential modulation of this enzyme in human 
osteoblastic cells. After 24 h, the exposure of osteoblasts 
to different concentrations of TAD down-regulated ARO 
mRNA expression in a concentration-dependent manner 
(p < 0.01, Fig. 3a). Moreover, TAD also inhibited ARO 
protein expression in a concentration-dependent manner, 
strongly suggesting an inhibition of this enzyme activity 
(p < 0.001, Fig. 3b), as previously suggested in vivo [6].
Androgen and estrogen receptors expression
To evaluate potential modulation of ARO by TAD, testos-
terone level in the cellular medium of osteoblastic cells 
exposed to TAD was measured by ELISA. Interestingly 
at 24 h testosterone levels were significantly increased in 
a concentration-dependent manner (Fig. 4, p < 0.05). Con-
versely, TAD treatment did not significantly modify estra-
diol levels at any experimental point (data not shown).
Then, a potential modulation of androgen and estrogen 
receptor by TAD was evaluated. Interestingly, TAD treat-
ment increased total AR expression in osteoblastic cells 
after 48 h exposure with a maximal effect obtained at a con-
centration of 10−7 M, as depicted in Fig. 5. Moreover, an 
increased nuclear translocation of AR was also observed, 
as evaluated by Western blot analysis, (data not shown), 
strongly suggesting an activation of androgen pathway. 
Estrogen receptor α (ERα) expression was also evaluated 
while ERβ mRNA and protein were barely detectable in 
these cells (data not shown), confirming results previously 
shown by others [13].
Interestingly, the ratio of total AR/ERα increased in a 
concentration-dependent manner strongly indicting a pref-
erential activity of androgen rather than estrogen pathway 
upon TAD exposure of osteoblastic cells (Fig. 6, p < 0.001). 
Also, Western blot analysis showed an increased expression 
of cytoplasmic and nuclear fractions of AR after different 
concentrations of TAD exposure at 48 and 72 h (Fig. 7).
Discussion
Our results confirm that significant amounts of PDE5 are 
expressed in human osteoblast SAOS-2 cells. Further, treat-
ment with the selective PDE5i TAD in vitro modulates 
aromatase enzyme activity. More notably, exposure of 
osteoblastic cells to TAD induced an increase in total AR 
expression and AR/ERα ratio. In particular, this effect was 
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Fig. 3  Expression of mRNA (a) and protein (b) ARO in osteoblasts, 
grown as described in Fig. 2. **p < 0.01; ***p < 0.001 versus CTL
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maximal after 24–48 h of treatment with different concen-
trations of TAD (10−8 and 10−7 M) and, accordingly, pro-
tein expression was increased after 24–48 h of exposure. 
Interestingly, a significant increase of testosterone level in 
the supernatant was observed after 48 h of TAD exposure, 
suggesting an overall decrease in ARO enzymatic activity 
after long-term in vitro human osteoblastic cells exposure 
to TAD. Interestingly, our findings show for the first time 
that exposure of osteoblastic cells to the PDE5i TAD can 
significantly decrease ARO expression and function.
PDE5 inhibitors promote their pharmacological effects 
by inhibiting PDE5, an enzyme responsible for the degra-
dation of cGMP. The raised levels of this cyclic nucleotide 
are thereby involved in the activation of the steroidogenic 
pathway and testosterone secretion, as recently PDE5 was 
identified in Leydig cells [14]. In the testis, cGMP signal 
transduction pathways are involved in a variety of local 
functions, based on autocrine or paracrine effects. In par-
ticular, cGMP has been suggested to influence motility in 
spermatozoa, development of testicular germ cells, relaxa-
tion of peritubular lamina propria cells, testosterone syn-
thesis in Leydig cells and dilatation of testicular blood 
vessels [15]. Thus, chronic treatment with sildenafil is able 
to exert stimulatory actions on testosterone production via 
cGMP accumulation [16]. In the present study, we did not 
investigate cGMP accumulation, but it is speculated that 
testosterone accumulation in the supernatant induced by 
TAD exposure might be either a direct effect via cGMP or 
indirect via aromatase inhibition.
The effects of aromatase inhibitors (AIs) on the human 
skeletal system due to systemic estrogen depletion are 
becoming clinically important due to their increasing 
use as an adjuvant therapy in postmenopausal women 
with breast cancer [17]. Cytochrome P450-ARO converts 
androgens into estrogens, and the role of estrogens in the 
pathophysiology of male osteoporosis is still under evalu-
ation [18]. Results published by Lormeau et al. confirmed 
the hypothesis according to which estrogens do not play a 
major role in the regulation of bone turnover in men [19]. 
Interestingly, they found that plasma levels of estradiol 
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were similar in both patients and controls. In our study, we 
provide for the first time evidence that chronic exposure to 
TAD in vitro is able to increase testosterone levels and, to 
interfere with androgen/estrogen receptor expression, sug-
gesting a significant modulation and increase of AR expres-
sion versus ER intracellular pathway.
Osteocytes and osteoblasts express high amount of ERα, 
but also AR as well. The increased androgen levels occur-
ring upon TAD exposure, might lead to the speculation that 
the increased AR expression could be responsible for a 
bone protective effect of TAD, since in our experience tes-
tosterone appears to play a predominant role in preserving 
male trabecular bone more than female bone [20]. Moreo-
ver, our recent unpublished observation shows that TAD 
increases AR expression in muscle cells in vitro (manu-
script in preparation) and other steroid responsive cells, 
further indicating that TAD can modulate, accordingly, sex 
steroid pathways in different cellular systems, known target 
of steroid hormones actions.
Using osteoblastic cells which express aromatase, 
AR, and ERα, Miki et al. demonstrated that the steroidal 
AI exemestane stimulated cell proliferation via both AR-
dependent and AR-independent pathways [21]. Interest-
ingly, recent in vitro data had demonstrated that the AI 
anastrozole was able to exert more remarkable antiprolif-
erative effects by prior activation of the AR by testosterone 
in breast cancer cells in vitro [22]. These findings further 
corroborate our results on the inhibitory effects of TAD on 
ARO and further highlight a potential new therapeutic use 
for the PDE5i molecules as potential agents for the treat-
ment of prostate cancer. It is known that men with pros-
tate carcinoma initially respond to treatments designed to 
inhibit androgen secretion or to block their action in target 
cells. Later the tumors may become refractory to androgen-
related therapies. Indeed, anastrozole [23] and selective 
AI [24] had been proposed for the treatment of men with 
advanced prostate cancer with inconsistent results. We 
herein speculate that chronic exposure to TAD, by enhanc-
ing AR after common rehabilitative treatments following 
prostate cancer surgery, might be one of the mechanisms 
involved in prostate cancer cell maintenance of responsive-
ness to anti-androgen therapy.
The study has some limitations. We did not investigate 
PDE5 or cGMP activities, as well as any transduction 
mechanism involved in these effects. In addition, we did 
not evaluate PDE11 transcript levels and potential cross-
talk inhibition of this isoenzyme by tadalafil in our experi-
mental model.
In conclusion, this is the first demonstration that TAD 
modulates ARO activity and AR expression in human 
steroid target cells in an in vitro model system. Further 
in vivo studies are then required to fully characterize the 
role of TAD in both ARO and AR expression and activity 
modulation to fully understand the biological implication in 
other androgen/estrogen target tissues as well as its poten-
tial clinical implication in patients with androgen-resista1nt 
prostate cancer.
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